D-RSC Database

The Duchenne Regulatory Science Consortium (D-RSC) Database is open to non-consortium members if approved by a data use committee consisting of neutral members of the consortium.

D-RSC Database

The Duchenne Regulatory Science Consortium (D-RSC) Database is a growing collection of datasets available to all qualified researchers, subject to review and approval by a data use committee. Depending on contributor preferences, requests may be reviewed by the data custodians, who continue to own the contributed data.

By making these datasets broadly available, D-RSC aims to expand access to data that can help accelerate drug development for Duchenne and Becker muscular dystrophy. The database includes data from clinical trials, natural history studies, patient registries, and clinical data collections.

The D-RSC Database is a living resource that will continue to grow as contributors make additional datasets available for sharing. Please check back regularly for new data releases.

Available Data

Parent Project Muscular Dystrophy’s Duchenne Registry

The Duchenne Registry is an online, patient-reported registry for individuals living with Duchenne muscular dystrophy, Becker muscular dystrophy or female carriers. This tranche includes data up to November 24, 2024.

ReveraGen Vamorolone Study

This Phase IIb study is a randomized, double-blind, parallel group, placebo and active-controlled study to evaluate the efficacy, safety, PD, and population PK of vamorolone administered orally at daily doses of 2.0 mg/kg and 6.0 mg/kg versus prednisone 0.75 mg/kg/day and placebo over a Treatment Period of 24 weeks, and to evaluate persistence of effect over a Treatment Period of 48 weeks in ambulant boys ages 4 to <7 years with DMD. 

Dataset only includes patients on control drugs (placebo and prednisone) up to 24 weeks. 

Catabasis 1 – MoveDMD (NCT02439216) 

This is a 3-part, Phase 1/2, multi-site study to evaluate the safety, efficacy, PK and PD of CAT-1004 in ambulatory male pediatric patients with a genetically confirmed diagnosis of DMD. Observations with an analysis assessment date occurring on or prior to a patient’s 1st dose of active treatment only available in this dataset. 

Catabasis 2 – PolarisDMD (NCT03703882) 

This is a randomized, double-blind, placebo-controlled, Phase 3, multisite study of edasalonexent in pediatric patients with DMD. Only placebo arm data available after baseline visit. 

The DMD Integrated Database (formerly known as the D-RSC Aggregated Database) combines patient-level data from the following clinical trials and observational studies. The information presented is provided by the data contributor and is shared as received. 

Contributor Study Type of Data Number of Participants Age Range Time Drugs included in study (active and control) Types of Variables 
Eli Lilly Phase 3 trial of Tadalafil Placebo arm of clinical trial 116 7-14 years up to 395 days Tadalafil (placebo arm only) Functional measures, Respiratory measures, Cardiac measures 
Summit Therapeutics Phaseout DMD Clinical Trial Data 39 5-10 years 52-56 weeks Ezutromid Functional Measures, Respiratory Measures, MRI/MRS, Northstar, PODCI 
Children’s Hospital of Philadelphia (CHOP) Clinical Study – Pulmonary Function Clinical study 66 0-24 years up to 3 years none Respiratory measures 
ImagingDMD Imaging DMD Natural History Study Natural history study 93 5-14 years up to 7 years none Functional measures, Myometry 
University of California, Davis DMD Natural History Natural history study 73 2-27 years up to 10 years none Functional measures, Respiratory measures, 
Myometry 
University of California, Davis Test/re-test data for Clinical Outcome Assessment (COA) COA 60 4-12 years 1 year none Functional measures, Respiratory measures 
Leiden University Medical Center Longitudinal Proteomic Study Biomarker Study 14 5-14 years up to 5 years none FVC, Drug Effects, Protein Biomarkers 
Pfizer Domagrozumab (PF-06252616) Study Placebo arm of clinical trial 40 6–15 years 49 weeks PF-06252616 (placebo arm only) Functional Measures, Respiratory Measures, MRI/MRS, Northstar, PUL, Muscle Strength 

Data standardization:

All datasets shared are fully de-identified and compliant with the terms and conditions specified by the data owners.  

The DMD Integrated Database has been mapped to current Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM) structures – https://www.cdisc.org/standards/therapeutic-areas/duchenne-muscular-dystrophy. Within the integrated database, datasets are combined so researchers will not be able to& identify participants of the studies or the specific trial from which individual participant observations originate. 

What is not in the database: 

  • Active treatment comparator data 

Data applicability:

  • Enhanced understanding and modeling of disease progression 
  • Advancement of drug development for specific disease indications 
  • Development of tools to simulate clinical trials for specific disease indications 
  • Constructing tools for placebo-arm best-practice modeling within clinical trials

Requirements for accessibility: 

  • Knowledge of SDTM is required for effective use of the data. Information and training on SDTM are available to approved researchers through the CDISC website. 
  • The use of the data is restricted to the approved applicant.